2010-2016 : Medical Doctor (M.D) Program at Universitas Airlangga School of Medicine, Surabaya
2016-2017 : Researcher at Public Health Department, Universitas Airlangga School of Medicine, Surabaya
2017-2019 : General Practitioner at Semen Gresik Hospital, Gresik
2020-2024 : Resident at Cardiology and Vascular Medicine Department, Universitas Airlangga School of Medicine - Dr. Soetomo General Hospital, Surabaya
2024-present : General Cardiologist, Universitas Airlangga School of Medicine - Dr. Soetomo General Hospital, Surabaya
2021 : Member of the European Society of Cardiology
2023 : Member of the American College of Cardiology
2023 : Member of the Young Community of The Asian Pacific Society of Cardiology
2024 : Fellow of the Indonesian Heart Association (FIHA)
2024 : Member of the International Society of Hypertension
2025 : Fellow of the American College of Cardiology (FACC)
EDUCATION
2010-2016 : Medical Doctor (M.D) Program at Universitas Airlangga School of Medicine, Surabaya
2020-2024 : Resident at Cardiology and Vascular Medicine Department, Universitas Airlangga School of Medicine - Dr. Soetomo General Hospital, Surabaya
RESEARCH, TEACHING, or OTHER INTERESTS
Cardiology and Cardiovascular Medicine, General Medicine, Medicine, Internal Medicine
42
Scopus Publications
Scopus Publications
RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention I Gde Rurus Suryawan, Yudi Her Oktaviono, Budi Baktijasa Dharmadjati, Aldhi Pradana Hernugrahanto, Mochamad Yusuf Alsagaff, David Nugraha, Made Edgard Rurus Surya Erlangga, Pandit Bagus Tri Saputra, Ricardo Adrian Nugraha Journal of Clinical Medicine, 2025 Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
The Emerging Role of Colchicine to Inhibit NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome and Interleukin-1β Expression in In Vitro Models Tri Astiawati, Mohammad Saifur Rohman, Titin Wihastuti, Hidayat Sujuti, Agustina Endharti, Djanggan Sargowo, Delvac Oceandy, Bayu Lestari, Efta Triastuti, Ricardo Adrian Nugraha Biomolecules, 2025 While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of myocardial infarction (MI) remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation and Interleukin-1β (IL-1β) expression in fibroblasts. 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 h to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 h. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post hoc tests. Hypoxia treatment significantly induced apoptosis-associated speck-like protein containing a CARD (ASC)-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
Targeting Inflammation with Galectin-3 and PIIINP Modulation Among ST-Segment Elevation Acute Coronary Syndrome Patients Underwent Delayed Percutaneous Coronary Intervention Saskia Dyah Handari, Mohammad Saifur Rohman, Djanggan Sargowo, Aulanni’am, Dahliatul Qosimah, Bayu Lestari, Ricardo Adrian Nugraha Biomedicines, 2025 Background/Objectives: ST-segment elevation acute coronary syndrome (STE-ACS) represents a significant global health challenge, with cardiac remodeling and fibrosis critically affecting recovery after percutaneous coronary intervention (PCI). Colchicine, known for its anti-inflammatory effects, may regulate key fibrotic markers such as Procollagen III N-terminal Propeptide (PIIINP) and Galectin-3. This study assesses colchicine’s effect on these biomarkers in STE-ACS patients undergoing delayed PCI. Methods: In this multicenter, randomized, double-blind trial, we examined colchicine’s impact on Galectin-3 and PIIINP in 164 STE-ACS patients undergoing early or delayed PCI. Patients received colchicine shortly after hospital admission. Biomarker changes were evaluated at 24 h and five days post-treatment using two-way ANOVA. Results: Clinical trials in the early PCI group revealed that Galectin-3 levels decreased significantly on day one (p < 0.01) and further on day five (p < 0.0001), indicating Primary PCI has benefits to inhibition of fibrosis beyond colchicine add-on treatment. But, in the delayed PCI group, Galectin-3 levels significantly increased on day one (p < 0.01), but the decrease observed by day five was not statistically significant. It is related that the benefits of colchicine treatment may exceed PCI implantation in preventing cardiac remodeling. In the delayed PCI group, PIIINP levels showed a significant reduction on day five (p < 0.0001). Conclusions: This Colchicine demonstrates novel efficacy in delayed PCI, with a significant increase in Galectin-3 and a sharp reduction in PIIINP, indicating its ability to control fibrosis. This positions colchicine as a breakthrough therapy for improving outcomes in STE-ACS patients with delayed intervention.
Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial Tri Astiawati, Mohammad Saifur Rohman, Titin Wihastuti, Hidayat Sujuti, Agustina Tri Endharti, Djanggan Sargowo, Delvac Oceandy, Bayu Lestari, Efta Triastuti, Ricardo Adrian Nugraha Journal of Clinical Medicine, 2025 Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β,and Galectin-3 expression and improving systolic–diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial was conducted at three hospitals in East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, and Dr. Iskak Hospital Tulungagung, between 1 June and 31 December 2023. A total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day 1 and day 5 by ELISA, while NT-proBNP was tested on days 5 and 30. Transthoracic echocardiography was also performed on day 5 and day 30. Results: By day 30, no significant improvements in systolic–diastolic echocardiography parameters had been shown in the colchicine group. However, colchicine reduced the level of NT-proBNP on day 30 more than placebo (ΔNT-proBNP: −73.74 ± 87.53 vs. −75.75 ± 12.44 pg/mL; p < 0.001). Moreover, colchicine lowered the level of Caspase-1 expression on day 5 and the levels of TGF-β and Galectin-3 expression on day 1. Conclusions: Colchicine can reduce NT-proBNP, Caspase-1, TGF-β, and Galectin-3 expression significantly among AMI patients. Colchicine administration was capable of reducing post-AMI inflammation, ventricular dysfunction, and heart failure but did not improve systolic–diastolic echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
Echocardiographic correlation of right ventricular-Pulmonary artery coupling to exercise tolerance in congenital heart disease-associated pulmonary hypertension Anudya Kartika Ratri, Ovin Nada Saputri, David Nugraha, Ricardo Adrian Nugraha, Alisia Yuana Putri, Meity Ardiana, Budi Susetyo Pikir, I Gde Rurus Suryawan Annals of Pediatric Cardiology, 2025 Background: Pulmonary arterial hypertension (PAH) is a chronic, progressive disease affecting the pulmonary vasculature, with a high mortality rate. Patients with PAH due to congenital heart disease (CHD) (World Health Organization Group 1) exhibit significantly reduced exercise tolerance compared to other PAH groups. Right ventricular (RV) dysfunction is a commonly used independent prognostic parameter in PAH. This study aimed to investigate an echocardiographic-derived parameter of RV-pulmonary artery (PA) coupling to exercise tolerance in PAH-CHD. Subjects and Methods: This cross-sectional study was performed on 51 consecutive patients with a confirmed diagnosis of PAH-CHD between February and March 2024. These patients underwent a 6-minute walk test (6MWT) and echocardiographic evaluation, including the measurement of tricuspid annular plane systolic excursion (TAPSE), pulmonary artery systolic pressure (PASP), TAPSE/PASP, and tricuspid regurgitation velocity (TRV) as parameters of RV function. The data were analyzed using the IBM SPSS Statistics software (version 26.0). Results: Fourteen men and 37 women aged 36.0 ± 11.2 years participated in this study. The most common CHD was atrial septal defect (88.2%) with left-to-right shunt (51.0%). The mean of 6MWT was 366.8 ± 60.6 m. There was a significant association between 6MWT and TAPSE (r = 0.330, P < 0.05), PASP (r = −0.273, P < 0.05), TAPSE/PASP (r = 0.392, P < 0.05), and TRV (r = −0.354, P < 0.05). Conclusion: The TAPSE/PASP is a simple echocardiographic parameter that correlates with RV function and exercise tolerance in patients with PAH-CHD.
Multiorgan pathological findings of severe COVID-19 in deceased patients: a post-mortem study in the Indonesian population Isnin Anang Marhana, Bambang Pujo Semedi, Ummi Maimunah, Achmad Lefi, Priangga Adi Wiratama, Etty Hary Kusumastuti, Edy Suyanto, Jilientasia Godrace Lilihata, Adhitri Anggoro, Lalu Galih Pratama Rinjani, Supriadi Supriadi, Alfian Nur Rosyid, Dwi Wahyu Indrawanto, Dyah Fauziah, Anny Setijo Rahaju, Nila Kurniasari, Alphania Rahniayu, Grace Ariani, Gilang Muhammad Setyo Nugroho, I Komang Rusgi Yandi, Ricardo Adrian Nugraha, Stephanie Natasha Djuanda, Andro Pramana Witarto Journal of Advanced Pharmacy Education and Research, 2025 Since the WHO declared the COVID-19 epidemic on March 11, 2020, there has been a notable increase in morbidity and death on a global scale. Despite the growing number of cases, limited data exists on the pathological changes in deceased COVID-19 patients, particularly concerning the lungs, heart, and liver. This study aims to describe the histopathological results in the lungs, heart, and Indonesian COVID-19 patients' livers that have died, providing insights into the multiorgan impact of se
Novel Impact of Colchicine on Interleukin-10 Expression in Acute Myocardial Infarction: An Integrative Approach Saskia Dyah Handari, Mohammad Saifur Rohman, Djanggan Sargowo, Aulanni’am, Ricardo Adrian Nugraha, Bayu Lestari, Delvac Oceandy Journal of Clinical Medicine, 2024 Background: Inflammation plays a critical role in myocardial infarction as a critical process in the development of heart failure, involving the development of cardiac fibrosis. Colchicine is a well-established anti-inflammatory drug, but its scientific application in controlling post-acute myocardial infarction (AMI) inflammatory processes has not been established. IL-10 is a key cytokine in modulating inflammatory responses, underscoring its potential as a crucial therapeutic target of colchicine. The objective was to explore the protective role of IL-10 modulated by colchicine in myocardial healing and repair following AMI, particularly cardiac fibrosis. Methods: The predicted protein of colchicine was assessed using WAY2DRUG PASS as probability active value. Proteins associated with colchicine, cardiac fibrosis, and acute myocardial infarction were analyzed with DisGeNET and Open Target databases. Analysis and visualization of protein–protein interactions were conducted using STRING and Cytoscape. A 3T3 cell line treated with CoCl2 was used to mimic hypoxic. HIF-1α and IL-10 expression were measured by flow cytometry and analyzed using a one-way ANOVA test. This observational clinical trial examined acute myocardial infarction patients undergoing immediate and delayed primary percutaneous coronary interventions. Subjects were randomized into control groups receiving placebo and intervention groups treated with colchicine. Assessments occurred at 24 h and five days after the intervention. IL-10 expression in the clinical trial was measured by ELISA and analyzed using a T-test. Results: Colchicine demonstrates promising bioactivity in treating acute myocardial infarction, with notably activity values highlighting its probable role as a tubulin antagonist (0.744), beta-tubulin antagonist (0.673), and NOS2 inhibitor (0.529). Its primary action targets IL-10, with the protein–protein interactions analysis indicating interactions between IL-10 and key inflammatory mediators—IL-1β, IFN-γ, CCL2, TNF, and TGF-β1—during acute myocardial infarction and cardiac fibrosis. Hypoxic conditions in the CoCl2-induced 3T3 cell model show significantly elevated HIF-1α compared to controls (p < 0.0001). Colchicine use significantly increased IL-10 expression in CoCl2-treated cells (p < 0.0001) and in AMI patients within five days (p < 0.05). Conclusions: Colchicine may bolster the anti-inflammatory response post-myocardial infarction by activating IL-10 pathways in fibroblasts and in clinical settings, potentially reducing inflammation after AMI. Further investigation into broader aspects of this pathway, particularly in cardiac fibroblasts, is required.
Myocardial injury mimicking acute myocardial infarction due to coronavirus infection in adults with pre-existing apical hypertrophic cardiomyopathy Radityo Bagus Wicaksono, Mochamad Yusuf Alsagaff, Ricardo Adrian Nugraha Journal of the Pakistan Medical Association, 2024 Symptoms of apical hypertrophic cardiomyopathy(ApHCM) can mimic acute myocardial infarction (AMI).Following COVID-19 infection, the elevation of troponinin ApHCM might be confusing, due to its similarity withAMI. We report the case of a 64-year-old male patientpresenting with exertional dyspnoea and chestdiscomfort. He had no history of coronary artery disease(CAD), but his swab test was positive for COVID-19. Thephysical examination was normal. The 12-leadelectrocardiogram showed a sinus rhythm of 78 bpm,with deep inverted T waves in leads V2 to V6, I, and aVL,and left ventricular hypertrophy. An Echocardiographicexamination showed an 18 mm apical wall thickness ofthe left ventricle. Laboratory tests revealed elevated hs-Troponin level, but diagnostic coronary angiography wasnormal. The diagnostic criteria fulfilled apical cardiachypertrophic cardiomyopathy. Coronavirus can induceatypical cardiovascular symptoms in pre-existing ApHCM.Misdiagnosis and failure to recognize may result ininappropriate therapy and delay in definitive treatment.Keywords: Troponin, COVID-19, Echocardiography,Electrocardiography, Hypertrophy, Angiography,Dyspnea, Infarction
Wellens Syndrome in a patient with a history of hypertension and chronic obstructive pulmonary disease: a case report Ririn Ramli, Makhyan Jibril Al Farabi, Bestya Presidiana, Ricardo Adrian Nugraha, Pandit Bagus Tri Saputra, Yudi Her Oktaviono Journal of the Pakistan Medical Association, 2024 Wellens syndrome, an ST Elevation Myocardial Infarction(STEMI) equivalent, is also known as T-wave left anteriordescending (LAD) coronary artery disease. Wellenssyndrome is characterized by a unique electrocardiogram(ECG) pattern that suggests a significant stenosis in theleft anterior descending coronary artery that warrantsimmediate intervention. Hereby, we present a case reportof Wellens syndrome in a patient with a history ofhypertension and chronic obstructive pulmonary disease(COPD) that may be potentially mistaken for pseudo-Wellens syndrome because the ECG pattern mimics leftventricular strain pattern (LVSP) in left ventricularhypertrophy (LVH). Thus, cautious examination of recentchest pain and ECG is important to differentiate Wellenssyndrome and LVSP in patients with hypertension andCOPD to perform early detection and aggressiveintervention since they may help to lessen the adverseresults.Keywords: Coronary Artery Disease, Myocardial,Electrocardiography, Chest Pain, Hypertrophy,Arrhythmias, Cardiac
Angiotensin converting enzyme inhibitor and coenzyme Q10 as adjunctive treatment for patients with ventricular septal rupture following late onset myocardial infarction: a case report Ryan Enast Intan, Dimas Rio Balti, Ricardo Adrlan Nugraha, Firas Farisi Alkaff, Sovia Salamah, Tan Nicko Octora Journal of the Pakistan Medical Association, 2024 Ventricular Septal Rupture (VSR) is a rare complication ofacute myocardial infarction and has a high mortality rate.Surgery is the definitive treatment. However, in hospitalswith limited facilities, treating acute myocardial infarctionpatients with ventricular septal rupture, is challenging. A74-year-old woman came to the emergency room of Dr.Koesma General Hospital, Tuban, East Java in December,2019 with late-onset Acute Myocardial Infarction. On thefollowing day, a new holosystolic murmur was heard inthe left lower sternal border with palpable thrill.Transthoracic echocardiography showed VSR with severepulmonary hypertension. This was followed by a drop inthe blood pressure to 80/50 mmHg. The blood pressurewas dependent on vasopressors until lisinopril andcoenzyme Q10 were introduced. After 3 months, thehaemodynamics of the patient were stable. This provedthat the use of angiotensin-converting enzyme andcoenzyme Q10 promotes more energy production,enables tissue healing and leads to balanced remodellingto increase the survival rate in cases of non-surgicaltreatment.Keywords: Lisinopril, Ventricular Septal Rupture, HeartMurmurs, Vasoconstrictor, Hemodynamics, Angiotensin’s,Infarction, Coenzymes
Quantification of hs-Troponin Levels and Global Longitudinal Strain among Critical COVID-19 Patients with Myocardial Involvement Mochamad Yusuf Alsagaff, Louisa Fadjri Kusuma Wardhani, Ricardo Adrian Nugraha, Tony Santoso Putra, Bagus Putra Dharma Khrisna, Makhyan Jibril Al-Farabi, Ruth Irena Gunadi, Yusuf Azmi, Christian Pramudita Budianto, Rosi Amrilla Fagi, Nadya Luthfah, Agus Subagjo, Yudi Her Oktaviono, Achmad Lefi, Budi Baktijasa Dharmadjati, Firas Farisi Alkaff, Budi Susetyo Pikir Journal of Clinical Medicine, 2024
Correlation between interleukin-6 expression in post-mortem core liver biopsy and degree of liver injury in patients with fatal COVID-19 Ummi Maimunah, Andi RK. Maharani, Gatot Soegiarto, Alphania Rahniayu, Vania A. Gunawan, Priangga A. Wiratama, Stephanie N. Djuanda, Supriadi Supriadi, Isnin A. Marhana, Bambang P. Semedi, Achmad Lefi, Etty H. Kusumastuti, Edi Suyanto, Jilientasia G. Lilihata, Adhitri Anggoro, Lalu GP. Rinjani, Alfian N. Rosyid, Dwi Wahyu, Dyah Fauziah, Anny S. Rahaju, Nila Kurniasari, Grace Ariani, Gilang MS. Nugroho, I KR. Yandi, Ricardo A. Nugraha Narra J, 2023
Differences in interleukin-6 and interleukin-17 expression in covid-19 post-mortem lung tissue biopsy compared with noncovid- 19 Etty Hary Kusumastuti, Priangga Adi Wiratama, Grace Ariani, Stephanie Natasha Djuanda, Alphania Rahniayu, Nila Kurniasari, Dyah Fauziah, Anny Setijo Rahaju, Isnin Anang Marhana, Alfian Nur Rosyid, Dwi Wahyu, Gilang Muhammad Setyo Nugroho, Adhitri Anggoro, I Komang Rusgi Yandi, Bambang Pujo Semedi, Jilientasia Godrace Lilihata, Ummi Maimunah, Supriadi Supriadi, Achmad Lefi Achmad Lefi, Lalu Galih Pratama Rinjani, Edi Suyanto, Ricardo Ardian Nugraha Pharmacognosy Journal, 2022
Interleukin-6 (IL-6) expression of lung tissue in COVID-19 patient severity through core biopsy post mortem Gilang Muhammad Setyo Nugroho, Isnin Anang Marhana, Etty Hary Kusumastuti, Bambang Pujo Semedi, Ummi Maimunah, Achmad Lefi, Edi Suyanto, Alfian Nur Rosyid, Dwi Wahyu, Priangga Adi Wiratama, Adhitri Anggoro, Komang I Rusgi Yandi, Stephanie Natasha Djuanda, Jilieanastasia Godrace Lilihata, Supriadi, Lalu Galih Pratama Rinjani, Ricardo Adrian Nugraha Annals of Medicine and Surgery, 2022
Prognostic Value of PCO2 Gap in Adult Septic Shock Patients: A Systematic Review and Meta-Analysis Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Prihatma Kriswidyatomo, Yudhistira Pradnyan Kloping, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Merlin Guntur Jaya, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Ricardo Adrian Nugraha, Department of Cardiology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Corinne Prawira Putri, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Dana Hendrawan Putra, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Nabila Ananda Kloping, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Taufan Adityawardhana, Medical Education Research, Staff Development Unit, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Niwanda Yogiswara, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, Nancy Margarita Rehatta, Department of Anaesthesiology, Reanimation, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia Turkish Journal of Anaesthesiology and Reanimation, 2022
Optic nerve and transcranial doppler ultrasonography for diagnosing increased intracranial pressure in adult traumatic brain injury pa-tients: A systematic review and meta-analysis Critical Care and Shock, 2020